AAA
OVID icon

Affinity Asset Advisors’s Ovid Therapeutics OVID Stock Holding History

Affinity Asset Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3M Sell
10,144,562
-491,756
-5% -$1.27M 1.23% 23
2026
Q1 		$23.6M Buy
10,636,318
+3,486,318
+49% +$6.23M 1.22% 27
2025
Q4 		$11.7M Buy
7,150,000
+4,500,000
+170% +$6.93M 0.66% 41
2025
Q3 		$3.44M Buy
2,650,000
+1,982,484
+297% +$1.72M 0.3% 61
2025
Q2 		$220K Hold
667,516
– – 0.03% 84
2025
Q1 		$208K Buy
+667,516
New +$410K 0.02% 91

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Affinity Asset Advisors's OVID Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Ovid Therapeutics (OVID) stake by 4.6% in Q2 2026, selling an estimated $1.27M and leaving 10,144,562 shares worth $27.3M. The position accounts for 1.23% of the portfolio, ranked #23.

Affinity Asset Advisors first reported a position in OVID in Q1 2025 and has held it in 6 quarters since. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Affinity Asset Advisors held 10,144,562 shares of Ovid Therapeutics worth $27.3M as of Q2 2026.
  • Affinity Asset Advisors sold 491,756 Ovid Therapeutics shares in Q2 2026, an estimated $1.27M.
  • Ovid Therapeutics made up 1.23% of Affinity Asset Advisors's portfolio in Q2 2026, its #23 holding.
  • Affinity Asset Advisors first reported a position in Ovid Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.